Key Insights

Highlights

Success Rate

85% trial completion

Published Results

299 trials with published results (27%)

Research Maturity

747 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.1%

136 terminated out of 1124 trials

Success Rate

84.6%

-2.0% vs benchmark

Late-Stage Pipeline

18%

199 trials in Phase 3/4

Results Transparency

40%

299 of 747 completed with results

Key Signals

299 with results85% success136 terminated

Data Visualizations

Phase Distribution

938Total
Not Applicable (216)
Early P 1 (10)
P 1 (230)
P 2 (283)
P 3 (135)
P 4 (64)

Trial Status

Completed747
Terminated136
Unknown108
Recruiting59
Withdrawn28
Not Yet Recruiting20

Trial Success Rate

84.6%

Benchmark: 86.6%

Based on 747 completed trials

Clinical Trials (1124)

Showing 20 of 20 trials
NCT07758595Phase 1Not Yet RecruitingPrimary

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease

NCT07688213Phase 2Recruiting

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

NCT05551741Phase 1CompletedPrimary

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

NCT07752784Phase 3Not Yet RecruitingPrimary

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

NCT07721467Phase 2Not Yet RecruitingPrimary

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

NCT07170150Phase 3RecruitingPrimary

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Phase 3RecruitingPrimary

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07399171Phase 2RecruitingPrimary

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

NCT07741526Phase 2Active Not RecruitingPrimary

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

NCT07306065Not ApplicableCompletedPrimary

University of Central Florida Music Study

NCT05519137Not ApplicableCompletedPrimary

Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia

NCT07234942Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

NCT07011745Phase 3RecruitingPrimary

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT06647498Phase 2RecruitingPrimary

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157Phase 2RecruitingPrimary

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06384573Phase 3Active Not RecruitingPrimary

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

NCT05269394Phase 2Active Not RecruitingPrimary

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT01760005Phase 2Active Not RecruitingPrimary

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT07177352Phase 3RecruitingPrimary

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT04867616Phase 2CompletedPrimary

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Scroll to load more

Research Network

Activity Timeline